Video
Author(s):
Experts in liver cancer treatment provide insight on real-world trials of immune checkpoint inhibitor combinations in HCC and opine on trial endpoints when immune therapy is utilized.
FDA Approves Zanidatamab for Previously Treated, Unresectable or Metastatic HER2+ Biliary Tract Cancer
Oncology Experts Preview Top Abstracts From the 2024 ESMO Congress
Liquid Biopsies, ctDNA Could Help Guide Gastrointestinal Cancer Management
Oncology Experts Preview Top Abstracts From the 2024 ASCO Annual Meeting
Molecular Testing Helps First-Line Treatment Landscape Evolve in Pancreatic Cancer
2024 Updates in GI Cancer Feature FLOT Combinations, Restricted FDA Approvals by PD-L1 Expression, and More
Dr Caimi on Early Data for LMY-920 in R/R B-Cell NHL
Navigating a “Sea Change” in Frontline Urothelial Carcinoma Treatment
Dr Scalici on Data for IMNN-001 Plus SOC Chemotherapy in Advanced Ovarian Cancer
Dr Lin on the Safety of NKTR-255 in Enhancing Immune Recovery Post-Chemoradiation in Locally Advanced NSCLC